West Announces Third Quarter 20...(cost Tax September 30 ...),Health

Date:11/3/2009

cost Tax September 30, 2008 Restructuring (income) benefits 2008 ---- ------------- -------- -------- ---- Operating profit $98.5 $2.5 $(6.1) $- $94.9 Interest expense, net 10.5 - - - 10.5 ---- -- -- -- ---- Income before income taxes 88.0 2.5 (6.1) - 84.4 Income tax expense 20.0 0.9 (2.1) 3.3 22.1 Equity in net income of affiliated companies 0.8 - - - 0.8 --- -- -- -- --- Net income 68.8 1.6 (4.0) (3.3) 63.1 Less: net income attributable to noncontrolling interests 0.5 - - - 0.5 --- -- -- -- --- Net income attributable to common shareholders $68.3 $1.6 $(4.0) $(3.3) $62.6 ----- ---- ----- ----- ----- Net income per diluted share attributable to common shareholders $1.98 $0.05 $(0.11) $(0.09) $1.83 ----- ----- ------ ------ ----- Please refer to the "Notes to Non-GAAP financial measures" for more information. Non-GAAP measures are intended to explain or aid in the use of, not as a substitute for, the related GAAP financial measure.

West Pharmaceutical Services, Inc.

SUPPLEMENTAL INFORMATION AND NOTES TO NON-GAAP FINANCIAL MEASURES

For additional details, please see the attache
'/>"/>

SOURCE West Pharmaceutical Services, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study